Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell ...

Tolebrutinib, expected to soon be submitted for U.S. approval for nonrelapsing SPMS, was granted the FDA's breakthrough ...

AIIMS researchers claim to have made significant progress in developing chimeric antigen receptor (CAR) T-cell therapy, ...

Gilead Sciences (NASDAQ:GILD) said it has received FDA Breakthrough Therapy Designation for its antibody-drug conjugate ...

The FDA granted breakthrough therapy designation to dostarlimab for locally advanced dMMR/MSI-H rectal cancer, highlighting ...

Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, ...

Sanofi SNY announced that the FDA has granted a Breakthrough Therapy designation to its investigational oral BTK inhibitor, tolebrutinib, for treating adults with non-relapsing secondary ...

The Breakthrough Therapy designation is supported by data from the randomized, open-label phase 2 SOLSTICE trial.

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

Scientists have discovered a key protein that helps cancer cells avoid detection by the immune system during a type of ...